search
Back to results

Assessment of Memory in Children With Kabuki Syndrom (MEM-K)

Primary Purpose

Kabuki Syndrome

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
No arm intervention
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional other trial for Kabuki Syndrome focused on measuring Kabuki Syndrome, Intellectual Profile, Memory

Eligibility Criteria

6 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Child from 6 to 16 years old
  • Presents an already established diagnosis of Kabuki syndrome.
  • Free, informed and written consent signed by the participant's parents, and the investigator (at the latest inclusion day and before any research required by the research).

Exclusion Criteria:

  • Be under 6 years old or over 16 years old
  • Do not master the French language
  • Not having access to language
  • Deafness not paired
  • Blindness.

Sites / Locations

  • Genetic Departement, rare disease, personalized medicine

Outcomes

Primary Outcome Measures

CMS (selective motor control scale) main score
CMS main score

Secondary Outcome Measures

CMS (selective motor control scale) indexes
CMS indexes

Full Information

First Posted
May 23, 2018
Last Updated
November 30, 2018
Sponsor
University Hospital, Montpellier
search

1. Study Identification

Unique Protocol Identification Number
NCT03547609
Brief Title
Assessment of Memory in Children With Kabuki Syndrom
Acronym
MEM-K
Official Title
Study on the Mnemic Functioning of Children With Kabuki Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
June 8, 2018 (Actual)
Primary Completion Date
September 7, 2018 (Actual)
Study Completion Date
September 7, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Mnesic function has not, at present, been evaluated in patients with Kabuki Syndrome. Some data from the neuroimagery suggest an impairment of memory function. The objective of our study is to assess the mnesic function of children with Kabuki Syndrom.
Detailed Description
Kabuki Syndrome (SK - OMIM 147920 and 300867 ORPHA: 2322) is a rare genetic disease with a prevalence of approximately 1/32 000 and responsible for a malformation syndrome with mild to moderate intellectual impairment. SK is due to mutations in the KMT2D and KDM6A genes. As part of a national PHRC (AOM 07-090, clinicaltrial NCT01314534, The investigators were able to perform psychometric tests type WISC4 and MRI type VBM). Disability in SK is characterized by a heterogeneous cognitive profile with strengths and weaknesses when calculating IQ. Brain MRI reveals small hippocampi compared to controls. These 2 data are partly contradictory because the strengths of the patients with SK are a working memory and a verbal comprehension index high compared to the other indices of the tests WISC-IV. The objective of the research is to better understand the mnesic function of children with SK. 25 children aged 6 to 16 will be recruited. The diagnosis of SK will have been authenticated by the demonstration of a mutation in the KMT2D or KDM6A gene. The memory assessments will be conducted in one visit for each child, who will perform a memory assessment with a neuropsychologist, using the CMS scale.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kabuki Syndrome
Keywords
Kabuki Syndrome, Intellectual Profile, Memory

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Other
Intervention Name(s)
No arm intervention
Intervention Description
No arm intervention
Primary Outcome Measure Information:
Title
CMS (selective motor control scale) main score
Description
CMS main score
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
CMS (selective motor control scale) indexes
Description
CMS indexes
Time Frame
1 hour

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Child from 6 to 16 years old Presents an already established diagnosis of Kabuki syndrome. Free, informed and written consent signed by the participant's parents, and the investigator (at the latest inclusion day and before any research required by the research). Exclusion Criteria: Be under 6 years old or over 16 years old Do not master the French language Not having access to language Deafness not paired Blindness.
Facility Information:
Facility Name
Genetic Departement, rare disease, personalized medicine
City
Montpellier
State/Province
Herault
ZIP/Postal Code
34295
Country
France

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
28295206
Citation
Lehman N, Mazery AC, Visier A, Baumann C, Lachesnais D, Capri Y, Toutain A, Odent S, Mikaty M, Goizet C, Taupiac E, Jacquemont ML, Sanchez E, Schaefer E, Gatinois V, Faivre L, Minot D, Kayirangwa H, Sang KLQ, Boddaert N, Bayard S, Lacombe D, Moutton S, Touitou I, Rio M, Amiel J, Lyonnet S, Sanlaville D, Picot MC, Genevieve D. Molecular, clinical and neuropsychological study in 31 patients with Kabuki syndrome and KMT2D mutations. Clin Genet. 2017 Sep;92(3):298-305. doi: 10.1111/cge.13010. Epub 2017 May 18.
Results Reference
result

Learn more about this trial

Assessment of Memory in Children With Kabuki Syndrom

We'll reach out to this number within 24 hrs